published Heart Cell Atlas study. Expression was altered in DCM in all but the rarest heart cell populations. Genes identified as altered in DCM in bulk RNA-seq were compared with altered genes from each single-cell cardiac cell population. Greatest concordance between the two techniques was noted in fibroblasts, with 14 upregulated and 13 downregulated genes common across both analyses. Several of these genes were independently validated in an in vitro model of TGF β -treated human cardiac fibroblasts.

Conclusions DCM is a complex pathology involving interactions between multiple cardiac cell populations. Our analysis workflow improved resolution at the single-cell level, providing more accurate recapitulation of in vivo tissue heterogeneity. This unbiased approach has enabled the robust detection of unique disease-relevant transcriptomic alterations in specific cardiac cell populations in DCM.

Conflict of Interest None

9 INDUCED PLURIPOTENT STEM CELL-DERIVED ENDOTHELIAL CELLS FROM HUMAN DIABETIC DONORS CARRY AN IMPRINT OF THE DIABETIC MILIEU

¹Magdalini Eleftheriadou, ¹Hojjat Naderi Meskin, ¹Andrew Yacoub, ¹Thomas Morrison, ¹Victoria Cornelius, ²Chunbo Yang, ³Martha Gonzalez, ¹Sophia Kelaini, ¹Garret Carney, ¹Guillermo Lopez Campos, ¹Noemi Lois, ¹David Grieve, ¹Alan Stitt, ¹Andriana Margariti. ¹Queens University Belfast, Belfast, UK; ²Newcastle University; ³Cambridge University

10.1136/heartjnl-2021-BCS.9

Diabetic endotheliopathy is the main cause for impaired angiogenesis and reduced neovascularization that lead to microvascular injury and vascular complications. The pathogenic basis for vascular complications arising from diabetes is complex. Elucidation of key underlying mechanisms will help the development of novel therapies and the discovery of potential biomarkers. The ability to generate functional endothelial cells (ECs) from induced pluripotent stem cells (iPSCs) from small amounts of blood is a novel and powerful tool for cell-based therapies. Human iPSC-derived ECs (iPS-ECs) have a broad range of clinical applications including cell-based therapy, disease modelling and drug screening; they can be used in mechanistic studies towards the development of novel therapies and in the discovery of new biomarkers to be applied in regenerative medicine and treatment of diabetic vasculopathy. Here we utilize transcriptomic and proteomic technologies to assess patient-specific iPS-ECs from diabetic (DiPS-ECs) and non-diabetic (NiPS-ECs) donors 1,2,3,4 in order to investigate the mechanisms driving endotheliopathy in diabetes. Our in vitro and in vivo models recapitulate the effects of hyperglycaemia on the vasculature in the clinical setting. RNA-seq data showed that genes and proteins involved in angiogenesis and EC function were significantly downregulated in DiPS-ECs in comparison to NiPS-ECs ($n=3$, $p<0.05$). Specific epsins regulating VEGF-mediated angiogenesis were downregulated in DiPS-ECs, leading to increased signalling VEGF pathway activation⁶. Moreover factors involved in E-cadherin signalling, endothelial-to-mesenchymal transition and fibrosis were increased in DiPS-ECs. We detected abnormal capillary permeability and barrier integrity in DiPS-ECs using xCELLigence®. DiPS-ECs had significantly reduced barrier integrity and barrier recovery ($n=3$, $p<0.001$, $\pm$ SEM) and also displayed impaired tube formation in vitro ($n=3$, $\pm$ SEM, $p<0.05$). DiPS-ECs displayed impaired function demonstrated by

decreased blood flow recovery (BFR) compared to NiPS ECs ($n=3$) when injected to the hindlimb of mice following femoral artery ligation. Finally, our proteomic and transcriptomic analysis confirmed imbalances in several angiogenic genes including endothelial specific Roundabout protein 4 (ROBO4) that is highly involved in pathways related to angiogenesis, barrier stability and endothelial health⁷. Expression of ROBO4 was found to be impaired in DiPS-ECs and transcriptomic analysis along with in vitro and in vivo studies revealed its importance in vascular development and angiogenesis. Our data support the impaired angiogenic functionality of DiPS-ECs cells in vitro and in vivo and show that DiPS-ECs carry an imprint of the diabetic milieu which is reflected in their dysfunction. To the best of our knowledge, we have identified a novel disease-specific signature in diabetic iPS-ECs, therefore our human iPS-EC model may serve as a valuable tool to study biological pathways and identify new treatments for diabetes-induced endotheliopathy.

Conflict of Interest None

10 PRIMARY MITRAL REGURGITATION SUCCESSFULLY TREATED BY PERCUTANEOUS MITRAL VALVE LEAFLET REPAIR RESULTS IN POSITIVE CARDIAC REVERSE REMODELLING AND FUNCTIONAL IMPROVEMENT

¹Thomas Craven, ¹Pei Gee Chew, ¹Mirosława Gorecka, ¹Louise Brown, ¹Arka Das, ¹Amrit Chowdhary, ¹Nicholas Jex, ¹Sharmaine Thirunavukarasu, ¹Erica Dall'Armellina, ²Eylem Levelt, ³Dominik Schlosshan, ³Christopher Malkin, ³Daniel Blackman, ¹Sven Plein, ¹John Greenwood. ¹University of Leeds, Leeds, UK; ²University of Leeds, Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science; ³Leeds Teaching Hospitals NHS trust

10.1136/heartjnl-2021-BCS.10

Background Percutaneous mitral valve leaflet repair can be an effective treatment for primary mitral regurgitation (MR) patients deemed high-risk for surgery. Accurate assessment of cardiac reverse remodelling is essential to optimise future patient selection. Cardiovascular magnetic resonance (CMR) is the reference standard for cardiac volumetric assessment and compared to transthoracic echocardiography (TTE) provides superior reproducibility in MR quantification. Prior CMR studies have analysed cardiac reverse remodelling following percutaneous intervention in combined cohorts of primary and secondary MR patients. However, as aetiology of MR can significantly impact outcomes, focused studies are warranted. Therefore, we aimed to assess cardiac reverse remodelling and quantify changes in MR following percutaneous mitral valve leaflet repair for primary MR using the reference standard (CMR).

Methods 12 patients with at least moderate-severe MR on TTE were prospectively recruited to undergo CMR imaging and 6-minute walk tests (6MWT) at baseline and 6 months following percutaneous mitral valve leaflet repair (MitraClip). CMR protocol involved: left-ventricular (LV) short axis cines (bSSFP, SENSE-2, 10mm, no gap), transaxial right-ventricular (RV) cines (bSSFP, SENSE-2, 8mm, no gap), two and four chamber cines and aortic through-plane phase contrast imaging, planned at the sino-tubular junction. MR was quantified indirectly using LV and aortic stroke volumes.

Results 12 patients underwent percutaneous mitral valve leaflet repair (MitraClip) for posterior mitral valve leaflet prolapse, however 1 patient declined follow up after single-leaflet clip

Abstract 10 Figure 1 Reduction in indexed left ventricular (LV) end-diastolic volumes and mitral regurgitation 6-months after percutaneous mitral valve leaflet repair
Dashed black line represents mean values

Abstract 10 Table 1 Functional changes 6-months following percutaneous mitral valve leaflet repair

	Baseline	Follow up	p-value
6-minute walk test distance (m)	223±71	281±65	0.005
New York Heart Association functional class			0.002
I	0	6	
II	3	4	
III	8	1	
IV	0	0	

Abstract 10 Table 2 Changes in cardiac indices 6-months following percutaneous mitral valve leaflet repair

Cardiac Indices	Baseline	Follow up	p-value
LV end-diastolic volume (ml/m ²)	118±21	94±27	0.001
LV end-systolic volume (ml/m ²)	58±19	48±21	0.007
LV ejection fraction (%)	51±10	51±7.8	0.775
Left atrial volume (ml/m ²)	108±39	102±31	0.565
Mitral regurgitant volume (ml)	55±22	24±12	0.003
Mitral regurgitant fraction (%)	49±9.4	29±14	<0.001
RV end-diastolic volume (ml/m ²)	101±28	103±28	0.790
RV end-systolic volume (ml/m ²)	58±26	56±21	0.477
RV ejection fraction (%)	44±8.4	48±8.9	0.110
Right atrial area (cm ² /m ²)	17±4.5	18±4.3	0.508

Abbreviations: LV, left ventricular; RV, right ventricular.

detachment resulting in 11 patients (age 83±5 years, 9 male) completing follow up imaging. At 6-months: significant improvements occurred in New York Heart Association functional class and 6MWT distances (223±71m to 281±65m, p=0.005) (table 1) and significant reductions occurred in indexed left ventricular end-diastolic volumes (LVEDVi) (118±21ml/m² to 94±27ml/m², p=0.001), indexed left ventricular end-systolic volumes (58±19ml/m² to 48±21ml/m², p=0.007) and quantitated MR volume (55±22ml to 24±12ml, p=0.003) and MR fraction (49±9.4% to 29±14%, p<0.001) (table 2). There were no statistically significant changes in left ventricular ejection fraction (LVEF), right ventricular dimensions/ejection fraction or bi-atrial dimensions (table 2). All

patients demonstrated decreased LVEDVi and quantified MR (figure 1).

Conclusion Successful percutaneous mitral valve leaflet repair for primary MR results in reduction in MR, positive LV reverse remodelling, preservation of LVEF, and functional improvements. Larger CMR studies are now required to further guide optimal patient selection.

Conflict of Interest Nil

11

A 5 YEAR STUDY OF INFECTIVE ENDOCARDITIS MANAGED BY A MULTIDISCIPLINARY TEAM IN A REGIONAL CARDIOTHORACIC CENTRE: TRENDS IN REFERRAL, INFECTIVE ORGANISMS AND OUTCOMES

¹Rhys Wenlock, ¹Eleanor Thornton, ²Sally Curtis, ¹Michael Lewis, ¹Luke Holland, ¹Rachael James. ¹Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; ²Department of Microbiology, Brighton and Sussex University Hospitals NHS Trust

10.1136/heartjnl-2021-BCS.11

Introduction Infective endocarditis (IE) is associated with a protracted inpatient stay, prolonged intravenous antimicrobial therapy and significant morbidity and mortality.

Methods All patients with a diagnosis of IE at the Sussex Cardiac Centre (SCC) between 2016 and 2020 were included. Demographics, clinical characteristics, management, complications and outcomes were analysed. Logistic EuroSCORE, EuroSCORE II and Risk-E Scores were calculated for patients undergoing operative management.

Results In the 5-year period 202 patients had 209 diagnoses of IE. Seven patients had recurrent IE; 3 with the same organism but with persistent risk factors after initial treatment (Intravenous drug users [IVDU] n = 2 and colonic polyps n=1). IE cases increased yearly by approximately 4 cases per year (p<0.01). The increase was predominantly driven by cases from referring centres, with 41% transferred from other hospitals (n=85). Oral streptococci (n= 50), coagulase-positive staphylococci (n=43), non-oral streptococci (n=29) and enterococci (n=28) were the commonest organisms identified (figure 1). Only oral streptococci demonstrated a significant increase over time (p<0.05, figure 1). Men made up 78% (n=163) of cases, with a male predominance observed in all organism groupings. Surgical